Armagen - Company & Market Research Reports

ArmaGen is a privately held, clinical stage biotechnology company focused on developing revolutionary therapies for severe neurological disorders. Currently, ArmaGen has eight compounds in development. The company’s lead product candidates are AGT-182 for Hunter syndrome, which is in Phase 1 clinical trials, and AGT-181 for Hurler syndrome, which is in Phase 2 trials. ArmaGen’s headquarters and research operations are located in Calabasas, CA.

Mucopolysaccharidosis I (Hurler Syndrome) Pipeline Analysis 2018 (H1) - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments - Product Thumbnail Image

Mucopolysaccharidosis I (Hurler Syndrome) Pipeline Analysis 2018 (H1) - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

  • Report
  • 85 Pages
From
Mucopolysaccharidosis III (Sanfilippo syndrome) Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments - Product Thumbnail Image

Mucopolysaccharidosis III (Sanfilippo syndrome) Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

  • Report
  • 89 Pages
From
BBB Technologies: Novel CNS Drug Delivery Approaches, 2015 - 2030 - Product Thumbnail Image

BBB Technologies: Novel CNS Drug Delivery Approaches, 2015 - 2030

  • Report
  • 219 Pages
From
Advanced and Targeted Drug Delivery Market Segmentation, Analysis & Forecast to 2021 - Product Thumbnail Image

Advanced and Targeted Drug Delivery Market Segmentation, Analysis & Forecast to 2021

  • Report
  • 382 Pages
From
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H1 2018 - Product Thumbnail Image

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H1 2018

  • Drug Pipelines
  • 59 Pages
From
Parkinson's Disease Market: Pipeline Review, Developer Landscape and Competitive Insights - Product Thumbnail Image

Parkinson's Disease Market: Pipeline Review, Developer Landscape and Competitive Insights

  • Report
  • 204 Pages
From
Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 56 Pages
From
Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Mucopolysaccharidosis I (MPS I) (Hurler Syndrome ) Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 67 Pages
From
Lysosomal Storage Disorder Global Clinical Trials Review, H2, 2017 - Product Thumbnail Image

Lysosomal Storage Disorder Global Clinical Trials Review, H2, 2017

  • Clinical Trials
  • 213 Pages
From
Mucopolysaccharidosis Disorders Drug Development Pipeline Review, 2018 - Product Thumbnail Image

Mucopolysaccharidosis Disorders Drug Development Pipeline Review, 2018

  • Report
  • 98 Pages
From
Metachromatic Leukodystrophy - Competitive Landscape and Market Insights, 2018 - Product Thumbnail Image

Metachromatic Leukodystrophy - Competitive Landscape and Market Insights, 2018

  • Report
  • 58 Pages
From
Amyotrophic Lateral Sclerosis - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2027 - Product Thumbnail Image

Amyotrophic Lateral Sclerosis - Competitive Landscape, Market Insights, Epidemiology and Market Forecast-2027

  • Drug Pipelines
  • 300 Pages
From
Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Pipeline Review, H1 2018 - Product Thumbnail Image

Alpha L-Iduronidase (IDUA or EC 3.2.1.76) - Pipeline Review, H1 2018

  • Drug Pipelines
  • 52 Pages
From
N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Pipeline Review, H1 2018 - Product Thumbnail Image

N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 3.10.1.1) - Pipeline Review, H1 2018

  • Drug Pipelines
  • 48 Pages
From
Rett Syndrome - Pipeline Review, H2 2018 - Product Thumbnail Image

Rett Syndrome - Pipeline Review, H2 2018

  • Drug Pipelines
  • 122 Pages
From
Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2018 - Product Thumbnail Image

Metachromatic Leukodystrophy (MLD) - Pipeline Review, H1 2018

  • Drug Pipelines
  • 42 Pages
From
Parkinson's Disease - Pipeline Review, H1 2018 - Product Thumbnail Image

Parkinson's Disease - Pipeline Review, H1 2018

  • Drug Pipelines
  • 881 Pages
From
Rett Syndrome - Pipeline Review, H1 2018 - Product Thumbnail Image

Rett Syndrome - Pipeline Review, H1 2018

  • Drug Pipelines
  • 114 Pages
From
Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2018 - Product Thumbnail Image

Amyotrophic Lateral Sclerosis - Pipeline Review, H1 2018

  • Drug Pipelines
  • 487 Pages
From
Global Blood-Brain Barrier Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026 - Product Thumbnail Image

Global Blood-Brain Barrier Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2018 To 2026

  • Report
From
Loading Indicator
adroll